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The purpose of this study was to compare the effectiveness of moxibustion (MOX) treat-
ment at the GV4 and CV12 acupoints, and to determine the correlations between MOX
treatment and interleukin (IL)-6 and corticosterone levels in a collagen-induced arthritis
(CIA) mouse model. CIA mice were immunized twice intradermally over a 3-week interval
with bovine type II collagen. After the second immunization (day 21), MOX was applied to
the mouse equivalent of the GV4 and CV12 acupoints with a 1 mg moxa cone five times/
day. Clinical symptoms of CIA were observed three times/week until day 35. The concen-
trations of IL-6 and corticosterone in the blood samples were measured by immunoassay
kits. At day 35, the incidence of CIA was significantly decreased in mice treated with MOX
at the GV4 acupoint (78%, nZ 23, p< 0.05), compared to untreated CIA mice (100%) and
mice treated with MOX at the CV12 acupoint (100%). IL-6 and corticosterone levels were
significantly increased by immunization. IL-6 levels significantly decreased in mice
treated with MOX at the GV4 acupoint. These results suggest that MOX treatment sup-
pressed CIA at the GV4 acupoint, not at the CV12 acupoint, possibly through inhibition
of IL-6 production.1. Introduction
Moxibustion (MOX) has been used as a traditional therapy
for the treatment of some immune-related diseases [1,2].
According to traditional Chinese medicine, the Governor
Vessel (GV) meridian, located at the dorsal midline,
possesses the function of invigorating the body’s resistanceof Physiology, Showa University, S
acopuncture Instituteand eliminating the cold-damp sensation [3]. MOX treat-
ment at the GV meridian has been shown to suppress
arthritis and pain in rheumatoid arthritis patients in China
[4,5]. MOX has been used to treat autoimmune diseases
such as rheumatoid arthritis, to suppress arthritis, for pain
relief and to improve a person’s ability to perform activities
associated with daily living. However, the underlyingchool of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8555
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rheumatoid arthritis, interleukin-6 (IL-6) increases the
generation of T cells, B cells, macrophages, monocytes
and endothelial cells, and acts on specific receptors on
different target cells [6]. IL-6 induces the migration of
lymphocytes, and also induces the proliferation of T cells
and the production of antibodies from plasma cells [7]. IL-6
induces vascular endothelial cell growth factor (VEGF)
production from localized inflammatory sites and regulates
neovascularization in rheumatoid joints [8]. IL-6 also
promotes differentiation of osteoclasts [9]. Therefore, IL-6
is considered to be a key pathological pro-inflammatory
cytokine and is a target in anti-rheumatoid arthritis drug
developments [10].
The GV4 (Mingmen) acupoint, one of the commonly used
points from the GV meridian, has been utilized in treating
human immunological disorders [3,11] and inducing
immune modulation in mice [12]. GV4 is also an effective
acupoint for MOX treatment. Fang et al reported that
MOX treatment at the GV4 acupoint prevented the inci-
dence of and attenuated collagen-induced arthritis (CIA) in
an experimental mouse model [13]. The CIA mouse model,
created by immunizing mice with type II collagen in adju-
vant, is a widely used model of rheumatoid arthritis
[14,15]. CIA in mice is characterized by a severe swelling of
the paws associated with a massive infiltration of inflam-
matory cells into the joints. Progression of the disease
results in destruction of joints and severe deformities.
MOX treatment is performed by igniting moxa (Mug-
wort wool) cones on the skin, and can cause a mild burn
injury. After a burn injury, serum glucocorticoid levels
increase due to activation of the hypothalamic-pituitary-
adrenal (HPA) axis [16]. The HPA axis can be triggered by
various factors, such as tumor necrosis factor-alpha
(TNF-alpha), IL-1 and IL-6 released mainly from immune
cells [17,18].
The purpose of this study was to determine and compare
the effectiveness of MOX treatment at the GV4 acupoint,
and other acupoints such as Conception Vessel (CV) 12
(Zhongwan), in the CIA mouse model. The CV12 acupoint is
located on the abdominal wall, and is associated with the
pancreas. It can induce secretion of endogenous beta-
endorphin, which reduces the plasma glucose concentra-
tion in an insulin-dependent manner in diabetic rats. The
CV12 acupoint has also been utilized in the treatment of
human abnormal peristaltic movement [19]. Correlations
between MOX treatment and IL-6 and corticosterone levels
were also investigated.2. Materials and methodsFigure 1 Experimental procedure. Mice were immunized
with CII at the beginning of the experiment and received
a second immunization on day 21. After the second immuniza-
tion, MOX was performed at the GV4 acupoint (MOX(GV4)-
treated CIA group), or the CV12 acupoint (MOX(CV12)-treated
CIA group) five times a day on days 21, 23, 26, 28, 30 and 33.2.1. Animals
Male DBA/1 J mice, aged 7 weeks, were purchased from
Sankyo Labo Service Co., Ltd. (Saitama, Japan). Animals
were housed with free access to food and water, and
acclimatized to standard laboratory conditions (23C 3C,
55% 10% humidity, and 12 hour light/dark cycles) for
7 days. The Showa University Committee of Animal Care
and Use approved the study protocol.2.2. CIA mouse model
Type II collagen (CII) from bovine articular cartilage
(Collagen Techno Training Institute Ltd., Tokyo, Japan) was
solubilized at a concentration of 200 mg/50 mL in 0.01 M
acetic acid and the solution was emulsified in an equal
volume of Freund’s complete adjuvant (Difco Laboratories,
Detroit, MI, USA) on ice. Mice were injected intradermally
at the base of the tail with 0.1 mL of the emulsion. Twenty-
one days after the primary immunization, the mice
received a second immunization of 200 mg of CII in 0.1 mL
Freund’s incomplete adjuvant (Difco Laboratories) [12]
(Fig. 1).
2.3. MOX treatment
The mice were divided into five groups: (1) the untreated
control group; (2) the MOX(GV4)-treated control group
(MOX treatment was administered at the GV4 acupoint to
non-immunized mice); (3) the untreated CIA group; (4) the
MOX(GV4)-treated CIA group; and (5) the MOX(CV12)-
treated CIA group.
MOX was conducted by placing small pieces of a moxa
(1 mg Mugwort wool) cone directly onto the skin surface at
the relevant acupoint and then ignited. The 1 mg moxa
cone burned out in an instant.
After the second immunization, a 1 mg moxa cone was
applied to the GV4 or CV12 acupoints. The moxa cone was
ignited for 5 seconds on the skin surface, five times/day,
three times/week, until day 33 (Fig. 1). The location of the
mouse GV4 acupoint was determined according to the
corresponding human GV4 acupoint, which is located on the
lower middle dorsal midline. The location of the mouse
CV12 acupoint was determined according to the corre-
sponding human CV12 acupoint, which is located on the
middle ventral midline on the opposite side of the body to
GV4 (Fig. 2).
2.4. Assessment of arthritis
The clinical symptoms of arthritis were evaluated with
a visual scoring inspection, based on the degree of peri-
articular erythema, swelling and joint deformity. Inspec-
tions were carried out three times/week, from days 21 to
Figure 2 The photograph shows the position of the GV4 and
CV12 acupoints on the mouse. The GV4 acupoint is located on
the lower middle dorsal midline (arrow with a solid line). The
CV12 acupoint is located on the middle ventral midline (arrow
with a dotted line), on the opposite side of the body to the GV4
acupoint.
Figure 4 Effect of MOX on the incidence of CIA in mice. Data
represent the mean  SE. On day 23, CIA was not observed in
any group. The incidence of CIA was significantly decreased by
MOX treatment at the GV4 acupoint. : untreated CIA group
(n Z 22), e:e: MOX(GV4)-treated CIA group (n Z 23),eAe:
MOX(CV12)-treated CIA group (n Z 8). * P < 0.05 vs untreated
or MOX(CV12)-treated CIA group, respectively.
Moxibustion reduces inflammation and IL-6 in CIA 3135. Lesions on the four paws of each mouse were assessed
using previously described criteria [6], and assigned a score
of 0 to 4 as follows: 0Z normal (Fig. 3A); 1Zmild
inflammation of a single area (i.e., midfoot, ankle or toes;
Fig. 3B); 2Zmoderately severe arthritis involving toes and
ankle or midfoot; 3Z severe arthritis involving an entire
paw (Fig. 3C); 4Z severe arthritis resulting in ankylosis and
loss of joint movement. The clinical score given to each
mouse was the sum of the scores assigned to each of the
four paws.
2.5. Quantification of IL-6 in plasma
On day 35, blood was collected using heparin as the anti-
coagulant, centrifuged at 2000 rpm for 20 minutes, and the
plasma stored at e20C until analysis. Plasma IL-6 was
assayed using the Quantikine Mouse IL-6 immunoassay kit
(R&D Systems Inc., Minneapolis, MN, USA).
2.6. Quantification of corticosterone in serum
On day 35, blood was collected, centrifuged at 2000 rpm for
20 minutes, and the serum stored at e20C until analysis.Figure 3 Assessment of arthritis. (A) 0Z normal. (B) 1Z mild in
paw.Serum corticosterone levels were determined using the
AssayMax Corticosterone ELISA Kit (Assaypro, St. Charles,
MO, USA).
2.7. Statistics
Statistical analysis was performed using a one-way analysis
of variance (ANOVA) followed by Fisher’s PLSD for incidence
of CIA and Student t test for clinical score of CIA, the levels
of IL-6 and corticosterone. All data are expressed as the
mean SE and differences were considered significant
when p< 0.05.
3. Results
3.1. Incidence of CIA
Arthritis was not observed in the untreated control and
MOX(GV4)-treated control groups. Mild inflammation wasflammation of a toe. (C) 3Z severe arthritis involving an entire
Figure 5 Effect of MOX on the clinical score of CIA mice.
Data represent the mean  SE. The clinical score of CIA was
significantly decreased by MOX treatment at the GV4 acupoint
on day 35. : untreated CIA group (n Z 22), e:e: MOX(GV4)-
treated CIA group (n Z 23), eAe: MOX(CV12)-treated CIA
group (n Z 8). * P < 0.05 vs untreated or MOX(CV12)-treated
CIA group, respectively.
Table 2 Effect of MOX on levels of corticosterone in
mouse plasma on day 35.
group n corticosteron
(ng/mL)
untreated normal 5 4.6 0.8
MOX(GV4)-treated
normal
5 3.2 0.5
untreated CIA 5 10.3 2.1
MOX(GV4)-treated
CIA
5 9.9 2.5
The level of corticosterone significantly increased in the
untreated CIA group (n Z 5, P < 0.05) and the MOX (GV4)-
treated CIA group (n Z 5, P < 0.05), compared to untreated
normal group. Results are expressed as meanSE.
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CIA increased in each group over time. At day 28, the
incidence of CIA in the MOX(GV4)-treated CIA group (57%,
nZ 23) was significantly lower than in the untreated CIA
group (91%, nZ 22, p< 0.01). On day 30, the incidence of
CIA in the MOX(GV4)- treated CIA group (61%, nZ 23) was
significantly lower than in the MOX(CV12)-treated CIA group
(100%, nZ 8, p< 0.05). Clinical symptoms of arthritis were
not observed in 22% of mice in the MOX(GV4)-treated CIA
group at day 35 (Fig. 4). Increases in the clinical score of
CIA also coincided with increases in the incidence of CIA in
each group. However, at day 35, the clinical score of CIA in
the MOX(GV4)-treated CIA group (5.7 1.0) was signifi-
cantly lower than that of the untreated CIA group
(8.4 0.7, p< 0.05) and the MOX(CV12)-treated CIA group
(8.3 1.3, p< 0.05; Fig. 5). In the MOX(GV4)-treated CIA
group, the clinical score of CIA was lower than the other
groups at each time point from day 28 to day 35.Table 1 Effect of MOX on levels of IL-6 in mouse plasma
on day 35.
group n IL-6 (pg/mL)
untreated normal 18 1.5 0.6
MOX(GV4)-treated
normal
17 1.4 0.2
untreated CIA 18 89.5 17.0
MOX(GV4)-treated
CIA
22 42.0 10.4
The level of IL-6 significantly increased in the untreated CIA
group (nZ 18, P < 0.001) and the MOX(GV4)-treated CIA group
(n Z 22, P < 0.001), compared to the untreated normal group.
The MOX(GV4)-treated normal group (n Z 18) was performed
moxibustion at GV4 with 5 times a day, 3 times a week till day
35 without immunization. Results are expressed as meanSE. In
CIA model, the level of IL-6 was significantly decreased by MOX
treatment (P < 0.05).3.2. Levels of IL-6 in plasma
On day 35, plasma IL-6 levels were 1.5 0.6 pg/mL in
the untreated control group (nZ 18) and 1.4 0.2 pg/mL
in the MOX(GV4)-treated control group (nZ 17), respec-
tively. In the untreated CIA group, plasma IL-6 levels
(89.5 17.0 pg/mL) were significantly higher than in the
untreated control group (nZ 18, p< 0.05), and were
significantly decreased by MOX treatment at the GV4 acu-
point (42.0 10.4 pg/mL, nZ 22, p< 0.05; Table 1).
3.3. Levels of corticosterone in serum
The levels of corticosterone on day 35 in the untreated CIA
and MOX(GV4)-treated CIA groups were 10.3 2.1 ng/mL
and 9.9 2.5 ng/mL, respectively. These levels were
significantly higher than in the untreated control group
(4.6 0.8 pg/mL) and the MOX(GV4)-treated control group
(3.2 0.5 pg/mL; Table 2).
4. Discussion
The results from this study clearly demonstrate that MOX
treatment at the GV4 acupoint reduced the incidence and
clinical score of CIA, and significantly decreased the high
levels of IL-6 in CIA mice.
In humans, many acupoints are located along the GV and
CV meridians. They have special relationships with the
liver, kidney, uterus and brain, and thus influence these
structures physiologically and pathologically. In this study,
MOX was performed at the GV4 (Mingmen) acupoint, which
is an effective acupoint for human immunological disorders
[3,11], and the CV12 (Zhongwan) acupoint, which is related
to gastrointestinal movement and associated with the
pancreas [19]. In this study, MOX treatment at the GV4
acupoint significantly reduced the incidence and develop-
ment of arthritis in CIA mice. CV12, however, was not an
effective acupoint. The effectiveness of MOX is not only
due to its thermal effect. To achieve the best therapeutic
efficacy, it is important to position MOX at the correct
acupoint, where its thermal effect may stimulate immune
suppression, which in turn suppresses arthritis.
Blocking IL-6 activity with the anti-IL-6 receptor anti-
body tocilizumab significantly reduces the disease activity
Moxibustion reduces inflammation and IL-6 in CIA 33of rheumatoid arthritis, indicating that IL-6 is strongly
involved in the pathogenesis of rheumatoid arthritis
[20e22]. In the current study, plasma IL-6 levels were
significantly decreased by MOX(GV4) treatment, and the
incidence and development of arthritis in CIA mice was also
suppressed. These data suggest that MOX(GV4) treatment
may inhibit rheumatoid arthritis pathology through the
suppression of IL-6 generation.
MOX treatment caused a small burn injury and inflam-
mation at the acupoint. A previous report has shown that
increased circulating levels of glucocorticoids are present
in the serum after a burn injury [16]. The current study
showed that serum corticosterone levels were increased in
the untreated CIA and MOX(GV4)-treated CIA groups,
compared to the untreated control group. However, there
were no differences in corticosterone levels between the
untreated control and the MOX(GV4)-treated control
groups. This result implies that MOX treatment does not
influence serum corticoid levels.
In conclusion, the results from the current study suggest
that MOX treatment at the GV4 acupoint may improve
immune-related diseases through inhibition of IL-6, and
that MOX treatment at the CV12 acupoint is ineffective.Acknowledgments
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